Will DENTSPLY SIRONA’s (XRAY) Interim CFO Appointment Signal a Shift in Financial Strategy?

• On November 25, 2025, DENTSPLY SIRONA Inc. announced that Michael Pomeroy had been appointed as interim Chief Financial Officer, bringing decades of finance experience across global sectors to the company while a search for a permanent CFO continues.
• The transition places a seasoned financial executive at the helm during a pivotal period of leadership change and ongoing business transformation.
• To better understand what this leadership transition means for DENTSPLY SIRONA, we'll examine how Mr. Pomeroy's interim appointment could shape the company's investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

DENTSPLY SIRONA Investment Narrative Recap

To be a shareholder in DENTSPLY SIRONA, you need confidence in the company’s ability to reignite growth and restore profitability through business transformation and product innovation. The interim appointment of Michael Pomeroy as CFO is not likely to materially affect the most important short-term catalyst, management’s push for operational streamlining and cost reduction to improve margins, but it does put extra attention on leadership execution, which remains a significant risk until more permanent appointments are made.

The company’s November 6, 2025 announcement of Q3 impairment charges totaling US$263 million stands out, as these were attributed to lower sales volumes and higher tariffs. This underscores the pressures facing DENTSPLY SIRONA, particularly as leadership transitions coincide with structural challenges that could impact margins and investor confidence if not managed decisively. Yet, for all the efforts to address these headwinds...

Read the full narrative on DENTSPLY SIRONA (it's free!)

DENTSPLY SIRONA is projected to achieve $3.9 billion in revenue and $502.2 million in earnings by 2028. This forecast assumes a 2.3% annual revenue growth rate and an earnings increase of $1.45 billion from current earnings of -$949.0 million.

Uncover how DENTSPLY SIRONA's forecasts yield a $12.96 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members shared three distinct fair value estimates for DENTSPLY SIRONA ranging from US$12.96 to US$34.81 per share. Several participants point to the persistent sales weakness and margin pressures discussed above, reminding you that future returns may depend on resolving these underlying business issues, explore all these perspectives to inform your next steps.

Explore 3 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth over 3x more than the current price!

Build Your Own DENTSPLY SIRONA Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free DENTSPLY SIRONA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com